Multicentre study of neoadjuvant chemotherapy for stage I and II oesophageal cancer. Issue 7 (4th April 2016)

• Record Type: Journal Article
• Authors: Bekkar, S; Gronnier, C; Renaud, F; Duhamel, A; Pasquer, A; Théreaux, J; Gagnière, J; Meunier, B; Collet, D; Mariette, C; Dhahri, A; Lignier, D; Cossé, C; Regimbeau, J-M; Luc, G; Cabau, M; Jougon, J; Badic, B; Lozach, P; Bail, J P; Cappeliez, S; El Nakadi, I; Lebreton, G; Alves, A; Flamein, R; Pezet, D; Pipitone, F; Stan-Iuga, B; Contival, N; Pappalardo, E; Coueffe, X; Msika, S; Mantziari, S; Demartines, N; Hec, F; Vanderbeken, M; Tessier, W; Briez, N; Fredon, F; Gainant, A; Mathonnet, M; Bigourdan, J M; Mezoughi, S; Ducerf, C; Baulieux, J; Mabrut, J-Y; Bigourdan, J M; Baraket, O; Poncet, G; Adam, M; Vaudoyer, D; Jourdan Enfer, P; Villeneuve, L; Glehen, O; Coste, T; Fabre, J-M; Marchal, F; Frisoni, R; Ayav, A; Brunaud, L; Bresler, L; Cohen, C; Aze, O; Venissac, N; Pop, D; Mouroux, J; Donici, I; Prudhomme, M; Felli, E; Lisunfui, S; Seman, M; Godiris Petit, G; Karoui, M; Tresallet, C; Ménégaux, F; Vaillant, J-C; Hannoun, L; Malgras, B; Lantuas, D; Pautrat, K; Pocard, M; Valleur, P; Lefevre, J H; Chafai, N; Balladur, P; Lefrançois, M; Parc, Y; Paye, F; Tiret, E; Nedelcu, M; Laface, L; Perniceni, T; Gayet, B; Turner, K; Filipello, A; Porcheron, J; Tiffet, O; Kamlet, N; Chemaly, R; Klipfel, A; Pessaux, P; Brigand, C; Rohr, S; Carrère, N; Da Re, C; Dumont, F; Goéré, D; Elias, D; Bertrand, C;
• Is Part Of: British journal of surgery. Volume 103:Issue 7(2016)
• Page Start: 855
• Page End: 862
• Publication Date: 2016-04-04
• Subjects: Surgery -- Periodicals; 617.005
• DOI: 10.1002/bjs.10121
• Languages: English
• ISSNs: 0007-1323

Abstract

Abstract: Background: The benefit of neoadjuvant chemotherapy (NCT) for early-stage oesophageal cancer is unknown. The aim of this study was to assess whether NCT improves the outcome of patients with stage I or II disease. Methods: Data were collected from 30 European centres from 2000 to 2010. Patients who received NCT for stage I or II oesophageal cancer were compared with patients who underwent primary surgery with regard to postoperative morbidity, mortality, and overall and disease-free survival. Propensity score matching was used to adjust for differences in baseline characteristics. Results: Of 1173 patients recruited (181 NCT, 992 primary surgery), 651 (55·5 per cent) had clinical stage I disease and 522 (44·5 per cent) had stage II disease. Comparisons of the NCT and primary surgery groups in the matched population (181 patients in each group) revealed in-hospital mortality rates of 4·4 and 5·5 per cent respectively ( P = 0·660), R0 resection rates of 91·7 and 86·7 per cent ( P = 0·338), 5-year overall survival rates of 47·7 and 38·6 per cent (hazard ratio (HR) 0·68, 95 per cent c.i. 0·49 to 0·93; P = 0·016), and 5-year disease-free survival rates of 44·9 and 36·1 per cent (HR 0·68, 0·50 to 0·93; P = 0·017). Conclusion: NCT was associated with better overall and disease-free survival in patients with stage I or II oesophageal cancer, without increasing postoperative morbidity. Abstract : Improves survival